🔗 Share this article TikTok Influencers Driving Parallel Market for Unlicensed Slimming Drug A shadow economy for unapproved weight-loss medications is being driven by social media fitness personalities and vendors on messaging platforms, based on new investigations. Experimental Drug Gaining Popularity Via Social Media Retatrutide, which remains in research studies, is being promoted by online personalities for its supposed fat-burning properties. Followers are encouraged to contact these profiles privately for supplier links, while also obtaining promotional offers. Thriving Commerce on Messaging Platforms Separately, a robust trade exists on Telegram, where groups with thousands of participants share comparison images, injection guides and assertions of rapid British shipping. Vendors promote the substance there before directing buyers to WhatsApp for transactions. Understanding The Experimental Drug This medication is an investigational injection created by US drugmaker Eli Lilly. The treatment targets three intestinal hormones – glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide and pancreatic hormone. Early trials indicate it could help patients lose up to 25% of their total weight. Referred to as the “triple G”, the drug is being promoted online as the successor to Ozempic. Healthcare Professionals Express Concerns However, physicians and chemists have warned that the distribution of what is still an unlicensed drug in the United Kingdom is worrisome and could result in users injecting products of unknown origin. Some experts said the demand for the experimental drug could be linked to the increasing cost of approved weight loss products such as Mounjaro. Regulatory Position and Implementation Marketing retatrutide on social media or Telegram is illegal in the United Kingdom, as it is an unapproved medication that cannot be promoted or distributed for personal consumption under the British medical regulations. Several content creators try to sidestep the rules by referring to the substance as a “research chemical” or citing it as “not for human consumption”. The substance is not a controlled substance, but promotion and distribution can still violate medicines, advertising, and consumer regulations, risking penalties, prosecution or prison. Platform Reaction and Content Removal Based on the social media company, the platform has taken down problematic material and banned associated hashtags and query recommendations. The company said it was committed to maintaining the platform safe and allocating resources in strengthening compliance measures. Online Trading Activities Investigations also discovered communities with up to 9,000 participants selling the experimental drug using the platform's integrated discovery tool, which operates like a online catalog. Entering “retatrutide” immediately displays groups with thousands of users, filled with photos of slimming results, glowing reviews and step-by-step guides for mixing or injecting at residence. After moments of entering one community, a seller shared contact information, where the majority of transactions occur. The vendor sent an guidebook and guaranteed delivery within 48 hours. When asked whether the product was genuine, one seller said: “You can’t be sure.” Another provided a photo of a supposed testing documentation. Not one inquired about weight, health issues or previous experience. Product Details and Pricing Inside these groups, posts show dark colored packages with Royal Mail labels, claiming to include fresh supplies. One message read: “It took eight of us to load them this morning.” Customers can choose between dry substance containers, prepared at residence with purified liquid, or ready-to-use pens typically sold at £160 for 20mg. When questioned how long a injector should be used, sellers give conflicting responses varying between a few weeks to “depends on your body”. Platform Oversight and Safety Actions A representative for Telegram said it actively moderated dangerous material on its service including material that promoted the “misuse of controlled medications”. The organization noted that it removed “millions of pieces of harmful content each day”. Healthcare Expert Warnings “People are administering substances they can’t verify. Even if the research behind retatrutide is valid, these digital products may not include what they advertise,” stated a pharmacy expert, the director of pharmacy at a pharmacy service. A medical professional of Asda Online Doctor linked the increase in interest to current cost increases for approved slimming drugs such as Mounjaro. “With costs increasing, individuals are turning to online platforms. But fake treatments are highly risky. You cannot know what’s contained or whether the environment they were produced in was sterile,” she explained. Her team has previously seen individuals injured by personal administration from unverified suppliers. “We recognize the disappointment, but buying from Telegram or communication platforms is gambling with your health,” stated Wyllie. “These materials could be contaminated or incorrectly dosed.” Manufacturer Statement A spokesperson from the pharmaceutical company stated retatrutide was in phase 3 clinical trials and had not been evaluated or approved by any regulatory agency globally. “Consequently at this time no one can market [it] for human use,” they explained, noting that any product “falsely representing itself as a company experimental substance not yet authorized … may expose patients to possibly serious health risks”.